Octapharma USA announces FDA approval of cutaquig 16.5% for pediatric PI patients

Octapharma USA today announced the U.S. Food & Drug Administration (FDA) has approved cutaquig® [Immune globulin, Subcutaneous (Human)-hipp, 16.5% Solution] for the treatment of pediatric patients age 2 and older with primary humoral immunodeficiency (PI). The FDA previously approved cutaquig® for adults with PI.

“The FDA approval provides physicians and families with more treatment options for patients with primary immune disorders, which weaken the immune system and can allow infections and other health issues to occur more easily,” said Roger H. Kobayashi, M.D., Clinical Professor UCLA School of Medicine and National Consultant, Immune Deficiency Foundation. “The FDA approval also provides more flexible options by permitting more frequent or less frequent infusions, which can be advantageous based on a patient’s pharmacokinetic and clinical response.”

Patients and providers have the flexibility to administer cutaquig® at a lower dose more frequently or at a larger dose less frequently if desired. Patients who prefer less frequent injections may have the option of receiving therapy every other week. At the same time, physicians can prescribe daily dosing if patients respond better to more frequent therapy.

Cutaquig® provides enhanced convenience for a wider group of patients who want to customize therapy with their prescriber to best match patient lifestyle needs,” said Octapharma USA President Flemming Nielsen. “Octapharma is committed to providing people with immune disorders the life-saving therapies they need. Both the addition of the pediatric indication and the flexible dosing illustrate our commitment to ensure patients have access to lifesaving products that offer a variety of choices for therapy delivery.”

Flemming Nielsen, President, Octapharma USA

The FDA approval of cutaquig® is based on the results of two clinical trials, which observed 75 PI patients, 37 adults and 38 pediatric patients between ages 2 and 17. The patients received weekly infusions with cutaquig® during a 12-week wash-in/wash-out period followed by a 12-month efficacy period. The main objective of the research was to assess the efficacy of cutaquig® in preventing serious bacterial infections, defined as bacteremia/sepsis, bacterial meningitis, osteomyelitis/septic arthritis, bacterial pneumonia and visceral abscess. No serious bacterial infections were reported.

Baby News

Related Posts

Research shows the importance of stopping drug use in early adulthood

Comments Off on Research shows the importance of stopping drug use in early adulthood

Kudos Diapers Review | The Picky Eater

Comments Off on Kudos Diapers Review | The Picky Eater

Healthiest Bread Guide 2021 (The Best Breads For You!)

Comments Off on Healthiest Bread Guide 2021 (The Best Breads For You!)

Autism, ADHD and school absence are associated with increased risk for self- harm in adolescents

Comments Off on Autism, ADHD and school absence are associated with increased risk for self- harm in adolescents

New parents slapped with surprise bills for treating newborns

Comments Off on New parents slapped with surprise bills for treating newborns

Study shows how whole genome sequencing could benefit children with cancer

Comments Off on Study shows how whole genome sequencing could benefit children with cancer

Pumpkin and Sweet Potato Soup

Comments Off on Pumpkin and Sweet Potato Soup

New research may open a window to treating aggressive form of B-cell acute lymphoblastic leukemia

Comments Off on New research may open a window to treating aggressive form of B-cell acute lymphoblastic leukemia

Children produce a much more robust antibody response to a SARS-CoV-2 infection than 18+

Comments Off on Children produce a much more robust antibody response to a SARS-CoV-2 infection than 18+

Chocolate Banana Smoothie – Super Healthy Kids

Comments Off on Chocolate Banana Smoothie – Super Healthy Kids

Study finds high level of resilience among children and adolescents living with glaucoma

Comments Off on Study finds high level of resilience among children and adolescents living with glaucoma

CDC encourages 16-and-17-year-old adolescents to receive COVID-19 booster shot

Comments Off on CDC encourages 16-and-17-year-old adolescents to receive COVID-19 booster shot

Create Account



Log In Your Account